UniQure needs to run another trial to prove its gene therapy "actually helps people with Huntington's disease," said a senior FDA official..
- FDA official declares UniQure's Huntington's gene therapy as 'failed'
- Requirement for another clinical trial undermines near-term development timeline
UniQure needs to run another trial to prove its gene therapy "actually helps people with Huntington's disease," said a senior FDA official.
AI-generated rewrite based on public information. Review official disclosures before trading.